CL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Colgate-Palmolive is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 who is unwilling to wait for a better entry. The stock has solid defensive characteristics and the recent Q1 report was better than expected on revenue, but the current setup is mixed: the price is slightly soft, momentum is only mildly bullish, options sentiment is cautious, insiders are heavy sellers, and earnings quality softened as net income, EPS, and gross margin all declined year over year. Wall Street remains broadly constructive, but not enough to justify an aggressive immediate buy at this price. My direct view: hold and wait for a cleaner entry.
CL closed at 87.30, slightly below the previous close of 87.36, with small weakness in both regular and post-market action. Trend-wise, the chart is still constructive: SMA_5 is above SMA_20 and SMA_200, which supports an overall bullish longer-term structure. MACD histogram is positive at 0.588, though it is contracting, so upside momentum is cooling. RSI_6 at 60.84 is neutral-to-bullish, not overbought. Price is sitting near the pivot of 86.361, with resistance at 88.454 and 89.747 and support at 84.267 and 82.974. Overall, the trend is positive but not strong enough to call a fresh momentum buy right now.
["Q1 revenue rose 8.41% year over year to $5.324 billion, beating expectations.", "The company benefited from strong international demand and continued pricing power.", "Analysts broadly raised price targets after the Q1 print, with several firms remaining Buy/Overweight.", "The stock is supported by a defensive consumer staples profile and bullish moving average structure."]
["Net income fell 6.38% year over year and EPS declined 5.88%, showing weaker profitability despite revenue growth.", "Gross margin slipped slightly to 60.59%, indicating some margin pressure.", "Insiders are selling heavily, with selling up sharply over the last month.", "Hedge funds are neutral and there are no strong institutional accumulation signals.", "Options positioning leans cautious with a put-call open interest ratio above 1.0.", "Barclays remains only Equal Weight and recently cut its target to 80, showing valuation and margin concerns."]
Latest quarter: 2026/Q1. Revenue increased to $5.324 billion, up 8.41% year over year, which is a strong top-line result. However, profitability weakened: net income fell to $646 million, EPS dropped to 0.80, and gross margin edged down to 60.59%. The growth trend is positive on sales, but earnings quality is not improving as quickly as revenue, so the quarter was good but not great from a long-term earnings perspective.
Analyst sentiment is mostly positive and has improved recently. Several firms raised targets after Q1, including UBS, Morgan Stanley, Deutsche Bank, JPMorgan, Goldman Sachs, Rothschild & Co Redburn, and BofA, with many maintaining Buy or Overweight ratings. Morgan Stanley turned notably more bullish, citing a return to 3%-4% organic sales growth. The main dissent is Barclays, which kept an Equal Weight rating and lowered its target to 80, showing some caution on the balance between volume, pricing, and costs. Wall Street pros are generally constructive, but the view is not unanimous.
